Drug Trial Radar · NCT00143273
Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation
Last checked: Nov 19, 2026Latest source record: Aug 10, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
497
Actual
Start
Jun 2004
Primary completion
Mar 2006
Study completion Mar 2006
Sponsor
- Lead sponsor
- Ligand PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Sep 2, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To establish the optimal dose of lasofoxifene that is fully effective in increasing the BMD in postmenopausal Asian women.
Conditions
- Osteoporosis
Interventions
lasofoxifeneDrug
0.05 mg tablets
PlaceboDrug
0 mg
LasofoxifeneDrug
0.25 mg tablets
LasofoxifeneDrug
0.5 mg tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effects of lasofoxifene compared to placebo on Bone Mineral Density (BMD) changes at the spine and hip after 1 year of treatmentTime frame: 12 months
Locations
17 sites in 3 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Pfizer Investigational Site
Fukuoka, Fukuoka, Japan
Pfizer Investigational Site
Kagoshima, Kagoshima-ken, Japan
Pfizer Investigational Site
Kagoshima, Kagoshima-ken, Japan
Pfizer Investigational Site
Miyazaki, Miyazaki, Japan
Pfizer Investigational Site
Fuchū, Tokyo, Japan
Pfizer Investigational Site
Kiyose, Tokyo, Japan
Pfizer Investigational Site
Minato-ku, Tokyo, Japan
Pfizer Investigational Site
Minato-ku, Tokyo, Japan
Pfizer Investigational Site
Setagaya-ku, Tokyo, Japan
Pfizer Investigational Site
Yonago-shi, Tottori, Japan
Pfizer Investigational Site
Kangnam-ku, Seoul, South Korea
Pfizer Investigational Site
Sonpagu, Seoul, South Korea
Pfizer Investigational Site
Youngdeungpo-gu, Seoul, South Korea
Pfizer Investigational Site
Changhua, Taiwan
Pfizer Investigational Site
Taipei, Taiwan
Pfizer Investigational Site
Taoyun 333, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.